GSK and CureVac Restructure Collaboration in New Licensing AgreementGSKDiscover GSK's acquisition of global rights for mRNA flu and COVID-19 vaccines from CureVac, with €400M upfront and potential €1.05B milestones. Gain insights into their strategic partnership and vaccine development goals.
EN
Agricultural News
Food News
Industrial News
Cosmetic News
Pharmaceutical News
Science News
